Positive top-line results from Phase II study of Ventyx’ VTX3232

San Diego, USA-based inflammatory diseases specialist Ventyx Biosciences (Nasdaq: VTYX) announced positive results from its Phase II study of oral, once-daily VTX3232 in patients with obesity and cardiovascular risk factors.

The 175- participant study examined VTX3232 versus placebo, alone or in combination with semaglutide, evaluating safety and tolerability as the primary endpoint, and effects on inflammation (measured by high-sensitivity C-reactive protein or hsCRP) as the secondary endpoint.

Participants treated with VTX3232 monotherapy in the modified analysis set (MAS) showed a 78% reduction in hsCRP at week 12 relative to baseline compared with a 3% increase in the placebo group (p<0.0001). Participants treated with VTX3232 in the full analysis set (FAS) showed a 64% reduction in hsCRP at week 12 relative to baseline compared with a 3% increase in the placebo group (p<0.0001). Participants treated with VTX3232 monotherapy also showed statistically-significant reductions in interleukin (IL)-6 (p<0.0001) to levels associated with reduced cardiovascular risk (IL-6 ≤1.65ng/L)1.